Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

10.88 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
News headline image
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Reports Q3 2025 Earnings Miss Amid Accelerated Clinical Pipeline Spending ↗
MindMed reports a wider-than-expected Q3 2025 loss as it accelerates its late-stage clinical trials for MM120, targeting anxiety and depression. 
Via Chartmill
Topics Earnings
News headline image
MindMed (MNMD) Q3 2025 Earnings Call Transcript ↗
MindMed (MNMD) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
MindMed Reports Q3 2025 Financial Results and Business Updates
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
MindMed to Participate in Upcoming Investor Conferences
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
MindMed Announces New Employee Inducement Grant
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed to Report Q3 2025 Financial Results on November 6, 2025
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed Announces New Employee Inducement Grant
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression ↗
Needham starts MindMed at Buy with a $28 target, citing strong Phase 3 prospects for MM120 in anxiety and depression and solid cash position. 
Via Benzinga
News headline image
The Insider Report: Panic Never Pays ↗
 
Via Benzinga
News headline image
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
News headline image
New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
News headline image
Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed to Participate in September Investor Conferences
From Mind Medicine Inc.
Via Business Wire
News headline image
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today ↗
Mind Medicine stock hasn't beaten the market over the last five years, but what comes next? 
Via The Motley Fool
News headline image
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed (MNMD) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Initial Public Offering
News headline image
MindMed Reports Strong Q2 2025 Results ↗
Via The Motley Fool
News headline image
1 Reason to Buy MindMed (MNMD) ↗
The U.S. public and the nation's politicians seem to be coming around to the idea of reforming psychedelic drug laws. Looser restrictions on research would help this company. 
Via The Motley Fool
Topics Cannabis Law Enforcement
News headline image
MindMed (MNMD) Q2 Net Loss Jumps 625% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
MindMed Reports Q2 2025 Financial Results and Business Updates
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed Announces New Employee Inducement Grants
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
From FN Media Group LLC
Via GlobeNewswire
News headline image
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
EQNX::TICKER_START (NYSE:CYBN),(NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:SAGE),(NASDAQ:MNMD),(NASDAQ:ATAI),(NEO:MMED) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.